uric acid and Acute Symptom Flare studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Research Excerpts

Excerpt	Relevance	Reference
"To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial."	9.69	A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023)
"To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach."	9.69	Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023)
"Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers."	9.51	Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022)
"In this randomized, placebo-controlled, single-blinded, multicentre trial, patients with acute gout flares within 72 h were randomized (1:1) to the placebo and febuxostat (40 mg/day) groups."	9.41	Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021)
"To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration."	9.27	Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018)
"Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy."	9.24	Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017)
"Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns."	8.12	A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022)
"In patients with gout, treating to target serum uric acid levels (sUA) of ≤6."	8.02	Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
" The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment."	7.30	Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023)
"Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints."	7.01	Uric acid en route to gout. ( Zhang, WZ, 2023)
"To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial."	5.69	A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023)
"To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach."	5.69	Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. ( Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Haslett, J; Horne, A; Mihov, B; Stamp, L, 2023)
"No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine."	5.69	Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. ( Chen, HC; Wei, JC; Yang, DH, 2023)
"Patients with hyperuricemia are among the high-risk group of postoperative gout attacks."	5.62	Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021)
"Early allopurinol initiation during an acute gout flare did not lead to significant changes in time to resolution, flare recurrence, and inflammatory markers."	5.51	Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. ( Manavathongchai, S; Pongsittisak, W; Satpanich, P, 2022)
"In this randomized, placebo-controlled, single-blinded, multicentre trial, patients with acute gout flares within 72 h were randomized (1:1) to the placebo and febuxostat (40 mg/day) groups."	5.41	Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. ( Cui, X; Geng, H; Jia, E; Jiang, Y; Li, B; Ma, W; Qiu, X; Wei, J; Xiao, M; Xiao, Y; Xie, J; Yao, X; Zhang, J; Zhang, Y; Zhong, L, 2021)
"To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration."	5.27	Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. ( Fujimori, S; Hidaka, Y; Ide, Y; Inoue, K; Kim, H; Sugimoto, M; Tamaki, S; Taniguchi, A; Yamamoto, T; Yamanaka, H, 2018)
"Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy."	5.24	Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). ( Adler, S; Bardin, T; Baumgartner, S; Bhakta, N; Fung, M; Keenan, RT; Khanna, PP; Kopicko, J; So, A; Storgard, C, 2017)
"Alcohol is recognized a risk factor for increased uric acid and gout flare."	5.22	The role of alcohol consumption in pathogenesis of gout. ( Nieradko-Iwanicka, B, 2022)
" In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout."	4.95	2016 updated EULAR evidence-based recommendations for the management of gout. ( Bardin, T; Barskova, V; Becce, F; Castañeda-Sanabria, J; Coyfish, M; Doherty, M; Guillo, S; Jansen, TL; Janssens, H; Lioté, F; Mallen, C; Nuki, G; Pascual, E; Perez-Ruiz, F; Pimentao, J; Punzi, L; Pywell, T; Richette, P; So, A; Tausche, AK; Tubach, F; Uhlig, T; Zavada, J; Zhang, W, 2017)
"Patients (n = 223) with gout taking allopurinol ≥300 mg daily attended a standardized gout assessment visit."	4.31	Predictors of Patient and Physician Assessments of Gout Control. ( Baumgartner, S; Choi, HK; Dalbeth, N; Frampton, C; Fung, M, 2023)
"In the treat-to-target, tight control NOR-Gout study patients started ULT with escalating doses of allopurinol."	4.12	One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Perez-Ruiz, F; Sexton, J; Uhlig, T, 2022)
"Pegloticase + methotrexate co-therapy was well-tolerated over 12 months, with sustained SU lowering, progressive gout flare reduction, and no new safety concerns."	4.12	A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an ( Bennett, R; Botson, JK; Chamberlain, J; Kenney, HM; LaMoreaux, B; Obermeyer, K; Peloso, PM; Peterson, J; Ramanathan, S; Song, Y; Tesser, JRP; Weinblatt, ME; Xin, Y; Zhao, L, 2022)
"Along with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares."	4.12	Plasma adsorption in refractory chronic gouty arthritis flare: A case report. ( Cui, TJ; Lei, Y; Tang, C; Wang, XH; Zhang, XM; Zheng, ZH, 2022)
"In patients with gout, treating to target serum uric acid levels (sUA) of ≤6."	4.02	Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021)
"Adequate uric acid control before surgery could prevent the postsurgical gout flare."	3.91	Clinical characteristics and risk factors for gout flare during the postsurgical period. ( Jeon, CH; Jeong, H, 2019)
" Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained."	3.30	Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial. ( den Broeder, AA; den Broeder, N; Flendrie, M; Peeters, IR; Taylor, WJ; van Herwaarden, N, 2023)
" The MGH Acupuncture Sensation Scale and adverse events related to acupuncture will be measured after each treatment."	3.30	Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. ( Chen, Z; Fang, MY; Huang, Y; Li, CN; Lin, FP; Liu, WH; Ma, Y; Tu, SH; Wang, B; Wang, Y; Xie, WX; Yu, LL; Zhang, RY; Zheng, CH, 2023)
" The incidence of adverse events was 50."	3.30	Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. ( Lee, J; Min, J; Saag, KG; Shin, S; Terkeltaub, R, 2023)
"Undertreated, gout can progress to palpable tophi and joint damage."	3.01	Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. ( Terkeltaub, R, 2023)
"Gout is a multifactorial metabolic and inflammatory disease that occurs when increased uric acid (UA) induce HU resulting in monosodium urate (MSU) crystal deposition in joints."	3.01	Uric acid en route to gout. ( Zhang, WZ, 2023)
"Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage."	3.01	Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. ( Dalbeth, N; Goodyear-Smith, F; Grey, C; Heather, M; Lutui, H; Ofanoa, M; Ofanoa, SM; Tu'akoi, S; van der Werf, B, 2021)
"Gout was known to affect people of high socioeconomic status."	2.82	Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices. ( Roman, YM, 2022)
"Gout is the most common form of inflammatory arthritis, and its incidence is highest in middle-aged and older patients."	2.72	Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. ( Kumar, M; Manley, N; Mikuls, TR, 2021)
"Gout is a disease in which the metabolic condition hyperuricemia leads to the formation of monosodium urate crystals, which provoke acute and chronic inflammatory responses through activation of the innate immune system."	2.66	Therapeutic approaches in the treatment of gout. ( Mandell, BF; Pillinger, MH, 2020)
"Gout is associated with lifestyle, body mass index (BMI) and comorbidities, including dyslipidaemia."	1.91	Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study. ( Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2023)
"Gout is the most common inflammatory arthritis and is almost exclusively managed in primary care, however the course and severity of the condition is variable and poorly characterised."	1.91	Cohort study investigating gout flares and management in UK general practice. ( Finnikin, S; Mallen, CD; Roddy, E, 2023)
"BACKGROUND Spinal gout is not so uncommon."	1.91	Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia. ( Gebreselassie, KZ; Kligora, C; Ranic, LM; Valancius, D, 2023)
"Gout is caused by monosodium urate (MSU) crystal deposition within joints."	1.91	Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare. ( Alhilali, M; Dalbeth, N; Jain, L; Popov, D; Poulsen, RC, 2023)
"Gout is the most common inflammatory arthritis in men with a rising incidence worldwide."	1.72	[Gout]. ( Tausche, AK, 2022)
"Gout is the most common inflammatory arthritis in men with a rising incidence worldwide."	1.62	[Gout]. ( Tausche, AK, 2021)
"Gout is often not adequately treated, and we aimed to apply urate lowering treatment (ULT) combined with individual information to achieve target serum urate (sUA) in clinical practice, and to identify predictors of achievement of this sUA target."	1.62	12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. ( Borgen, T; Haavardsholm, EA; Hammer, HB; Karoliussen, LF; Kvien, TK; Sexton, J; Uhlig, T, 2021)
"Patients with hyperuricemia are among the high-risk group of postoperative gout attacks."	1.62	Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. ( Fu, L; Liu, Y; Wen, J; Xu, C; Yan, T; Yang, H; You, Y; Yu, J; Zhan, D; Zhang, T, 2021)
"BACKGROUND Gout is a chronic disease characterized by deposition of monosodium urate crystals, typically manifesting as arthritis."	1.62	Gout Storm. ( Cardoso Nóbrega, V; Curcelli, EC; Junior, LAJ; Luiz da Silva, D; Martins, D; Matchil, NL; Okoshi, MP; Pacca, RL; Padovani de Toledo Moraes, M; Padovese, V; Pereira, FWL; Queiroz, DS; Silva, AM; Tonon, CR, 2021)

Research

Studies (70)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (11.43)	24.3611
2020's	62 (88.57)	2.80

Authors	Studies
Jatuworapruk, K	6
Grainger, R	5
Dalbeth, N	15
Taylor, WJ	6
Martins, D	1
Tonon, CR	1
Pacca, RL	1
Matchil, NL	1
Junior, LAJ	1
Queiroz, DS	1
Pereira, FWL	1
Silva, AM	1
Padovese, V	1
Padovani de Toledo Moraes, M	1
Luiz da Silva, D	1
Cardoso Nóbrega, V	1
Curcelli, EC	1
Okoshi, MP	1
Ofanoa, M	1
Ofanoa, SM	1
Heather, M	1
Tu'akoi, S	1
Lutui, H	1
Grey, C	1
van der Werf, B	1
Goodyear-Smith, F	1
Zhao, L	2
Zhao, T	1
Yang, X	1
Cao, L	1
Xu, R	1
Liu, J	1
Lin, C	1
Yu, Y	1
Xuan, D	1
Zhu, X	1
Liu, L	1
Hua, Y	1
Deng, C	1
Wan, W	1
Zou, H	1
Xue, Y	1
Xu, N	1
Han, X	1
Zhang, Y	4
Huang, X	1
Zhu, W	1
Shen, M	1
Zhang, W	2
Jialin, C	1
Wei, M	1
Qiu, Z	1
Zeng, X	1
Schlesinger, N	1
Brunetti, L	1
Androulakis, IP	1
Uhlig, T	7
Karoliussen, LF	6
Sexton, J	6
Kvien, TK	6
Haavardsholm, EA	6
Perez-Ruiz, F	3
Hammer, HB	6
Jia, E	2
Hu, S	4
Geng, H	2
Zhu, H	1
Xie, J	2
Xiao, Y	2
Jiang, Y	2
Xiao, M	2
Zhang, J	2
Tausche, AK	4
Orji, OC	1
López-Domínguez, MB	1
Sandoval-Plata, G	1
Guetta-Baranes, T	1
Valdes, AM	1
Doherty, M	3
Morgan, K	1
Abhishek, A	3
Coleman, GB	1
Frampton, C	3
Haslett, J	2
Drake, J	2
Su, I	1
Horne, AM	1
Stamp, LK	3
Choi, HK	3
Ortolan, A	1
Vio, S	1
Gallo, M	1
Lorenzin, M	1
Ramonda, R	1
Cipolletta, E	2
Di Battista, J	1
Grassi, W	1
Filippucci, E	1
Botson, JK	2
Tesser, JRP	2
Bennett, R	1
Kenney, HM	1
Peloso, PM	1
Obermeyer, K	2
Song, Y	1
LaMoreaux, B	2
Xin, Y	2
Chamberlain, J	2
Ramanathan, S	1
Weinblatt, ME	2
Peterson, J	2
Roman, YM	1
Saag, K	1
Parikh, N	1
Ong, S	1
La, D	1
LoCicero, K	1
Verma, S	1
Sainati, S	1
Grewal, S	1
Majjhoo, A	1
Mikhailidis, DP	1
Kouvari, M	1
Pangiotakos, DB	1
Fung, M	2
Baumgartner, S	2
Satpanich, P	4
Robinson, PC	4
Sun, M	3
Li, M	3
Xue, X	3
Terkeltaub, R	5
Wang, C	3
Wang, M	3
Lu, J	3
Ran, Z	3
Li, H	3
Ji, A	3
Sun, W	3
Li, X	3
He, Y	3
Liu, Z	4
Zhang, H	4
Wang, X	3
Ji, X	3
Li, C	4
Lei, Y	2
Cui, TJ	2
Wang, XH	2
Zhang, XM	2
Tang, C	2
Zheng, ZH	2
Tata, LJ	1
Fonseca, AC	1
Yang, DH	1
Chen, HC	1
Wei, JC	1
Lee, J	1
Min, J	1
Shin, S	1
Saag, KG	1
Provan, SA	1
Gebreselassie, KZ	1
Valancius, D	1
Ranic, LM	1
Kligora, C	1
Peeters, IR	1
den Broeder, AA	1
den Broeder, N	1
Flendrie, M	1
van Herwaarden, N	1
Wang, G	1
Zhuo, N	1
Popov, D	1
Jain, L	1
Alhilali, M	1
Poulsen, RC	1
McCormick, N	1
Yokose, C	1
Wei, J	2
Lu, N	1
Wexler, DJ	1
Aviña-Zubieta, JA	1
De Vera, MA	1
Stamp, L	1
Horne, A	1
Mihov, B	1
Chapman, PT	1
Zhang, WZ	1
Yu, LL	1
Li, CN	1
Fang, MY	1
Ma, Y	1
Wang, B	1
Lin, FP	1
Liu, WH	1
Tu, SH	1
Chen, Z	1
Xie, WX	1
Zhang, RY	1
Huang, Y	1
Zheng, CH	1
Wang, Y	1
Finnikin, S	1
Mallen, CD	1
Roddy, E	2
Lai, SW	1
Kuo, YH	1
Liao, KF	1
Zhuo, Y	1
Cai, X	1
Hou, Z	1
Zhu, Z	1
Fautrel, B	1
Belhassen, M	1
Hudry, C	1
Woronoff-Lemsi, MC	1
Levy-Bachelot, L	1
Van Ganse, E	1
Tubach, F	2
Stewart, S	1
Tallon, A	1
Gaffo, A	1
Zaidi, F	1
Narang, RK	1
Phipps-Green, A	1
Gamble, GG	1
So, A	3
Riches, P	1
Andres, M	1
Janssen, M	2
Joosten, LAB	1
Jansen, TL	3
Kurreeman, F	1
Torres, RJ	1
McCarthy, GM	1
Miner, JN	1
Merriman, TR	1
Pei, L	1
Xie, L	1
Wu, J	1
Zhang, X	1
Lu, B	1
Lu, Q	1
Huang, B	1
Zheng, F	1
Wang, P	1
Pietsch, DEW	1
Kubler, P	1
Pillinger, MH	1
Mandell, BF	1
Watson, L	1
Belcher, J	1
Nicholls, E	1
Muller, S	1
Mallen, C	2
Ebstein, E	1
Forien, M	1
Norkuviene, E	1
Richette, P	2
Mouterde, G	1
Daien, C	1
Ea, HK	1
Brière, C	1
Lioté, F	2
Petraitis, M	1
Bardin, T	3
Ora, J	1
Dieudé, P	1
Ottaviani, S	1
Ma, W	1
Li, B	1
Zhong, L	1
Yao, X	1
Qiu, X	1
Cui, X	1
Borgen, T	1
Nieradko-Iwanicka, B	1
Kumar, M	1
Manley, N	1
Mikuls, TR	1
Koto, R	1
Nakajima, A	1
Horiuchi, H	1
Yamanaka, H	2
Eskild, T	1
Lertnawapan, R	1
Hanvivadhanakul, P	1
Towiwat, P	1
Shi, L	1
Xu, C	1
Wen, J	1
Yang, H	1
You, Y	1
Zhan, D	1
Yu, J	1
Fu, L	1
Zhang, T	1
Liu, Y	1
Yan, T	1
Pongsittisak, W	1
Manavathongchai, S	1
Vargas-Santos, AB	1
Neogi, T	1
Tamaki, S	1
Ide, Y	1
Kim, H	1
Inoue, K	1
Sugimoto, M	1
Hidaka, Y	1
Taniguchi, A	1
Fujimori, S	1
Yamamoto, T	1
Morillon, MB	1
Singh, JA	1
Lassere, M	1
Christensen, R	1
Pascart, T	1
Grandjean, A	1
Capon, B	1
Legrand, J	1
Namane, N	1
Ducoulombier, V	1
Motte, M	1
Vandecandelaere, M	1
Luraschi, H	1
Godart, C	1
Houvenagel, E	1
Norberciak, L	1
Budzik, JF	1
Te Kampe, R	1
van Durme, C	1
van Eijk-Hustings, Y	1
Boonen, A	1
Jeong, H	1
Jeon, CH	1
Choi, HJ	1
Lee, CH	1
Lee, JH	1
Yoon, BY	1
Kim, HA	1
Suh, CH	1
Choi, ST	1
Song, JS	1
Joo, H	1
Choi, SJ	1
Lee, JS	1
Shin, K	1
Jun, JB	1
Baek, HJ	1
Pascual, E	1
Barskova, V	1
Becce, F	1
Castañeda-Sanabria, J	1
Coyfish, M	1
Guillo, S	1
Janssens, H	1
Nuki, G	1
Pimentao, J	1
Punzi, L	1
Pywell, T	1
Zavada, J	1
Keenan, RT	1
Khanna, PP	1
Kopicko, J	1
Bhakta, N	1
Adler, S	1
Storgard, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Open-Label [OL])[NCT03635957]	Phase 4	14 participants (Actual)	Interventional	2018-09-26	Completed
Pragmatic, Randomized, Multicenter, Double-blind, Controlled, Clinical Trial of Prednisolone Versus Colchicine for Acute Gout in Primary Care[NCT05698680]	Phase 4	314 participants (Anticipated)	Interventional	2023-01-18	Recruiting
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response t[NCT01493531]	Phase 3	610 participants (Actual)	Interventional	2011-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Serum uric acid (sUA < 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)

Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

Serum uric acid (sUA < 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)

Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)

Mean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52

Intervention	percentage of participants (Number)
Pegloticase With Methotrexate (MTX)	78.6

The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis. (NCT03635957)
Timeframe: Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52

Gout Flares

Intervention	mg/dL (Mean)
	Change at Week 14 - pre-infusion	Change at Week 14 - post-infusion	Change at Week 24 - pre-infusion	Change at Week 24 - post-infusion	Change at Week 36 - pre-infusion	Change at Week 36 - post-infusion	Change at Week 52
Pegloticase With Methotrexate (MTX)	-9.27	-9.31	-9.27	-9.48	-8.13	-9.41	-8.15

Mean rate of gout flares requiring treatment for the 6-month period from the end of Month 6 to the end of Month 12. (NCT01493531)
Timeframe: 12 Months

Subjects With ≥ 1 Target Tophus at Baseline Who Experience Complete Resolution of at Least 1 Target Tophus by Month 12

Intervention	Gout Flares (Mean)
Lesinurad 200 mg + Allopurinol	0.7
Lesinurad 400 mg + Allopurinol	0.8
Placebo + Allopurinol	0.9

Proportion of subjects with ≥ 1 target tophus at Baseline who experience complete resolution of at least 1 target tophus by Month 12 (NCT01493531)
Timeframe: 12 months

Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6.

Intervention	Proportion of Subjects (Number)
Lesinurad 200 mg + Allopurinol	0.314
Lesinurad 400 mg + Allopurinol	0.276
Placebo + Allopurinol	0.333

Proportion of subjects with an sUA level that is < 6.0 mg/dL by Month 6. (NCT01493531)
Timeframe: 6 months

Article	Year
Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature. Arthritis research & therapy, 2022, 02-26, Volume: 24, Issue:1 Topics: Adolescent; Adult; Child; Female; Glycogen Storage Disease; Gout; Humans; Retrospective Studies; Sym	2022
Does seasonality of the microbiota contribute to the seasonality of acute gout flare? Clinical and experimental rheumatology, 2022, Volume: 40, Issue:9 Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Microbiota; Symptom Flare Up; Uric	2022
When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy. Nature reviews. Rheumatology, 2022, Volume: 18, Issue:9 Topics: Biology; Gout; Gout Suppressants; Humans; Random Allocation; Randomized Controlled Trials as Topic;	2022
Moving the Needle in Gout Management: The Role of Culture, Diet, Genetics, and Personalized Patient Care Practices. Nutrients, 2022, Aug-31, Volume: 14, Issue:17 Topics: Aged; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care; Reproducibility of Results	2022
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. Drugs, 2023, Volume: 83, Issue:16 Topics: Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Uric Ac	2023
Uric acid en route to gout. Advances in clinical chemistry, 2023, Volume: 116 Topics: Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid	2023
How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:2 Topics: Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Symptom Flare	2020
Therapeutic approaches in the treatment of gout. Seminars in arthritis and rheumatism, 2020, Volume: 50, Issue:3S Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Mal	2020
The role of alcohol consumption in pathogenesis of gout. Critical reviews in food science and nutrition, 2022, Volume: 62, Issue:25 Topics: Alcohol Drinking; Alcoholic Beverages; Beer; Ethanol; Gout; Humans; Hyperuricemia; Symptom Flare Up;	2022
Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity. Drugs & aging, 2021, Volume: 38, Issue:7 Topics: Aged; Comorbidity; Gout; Gout Suppressants; Humans; Middle Aged; Symptom Flare Up; Uric Acid	2021
2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:1 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Delphi Technique; Directive Counse	2017

Article	Year
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. International journal for equity in health, 2021, 12-23, Volume: 20, Issue:1 Topics: Australia; Gout; Humans; Native Hawaiian or Other Pacific Islander; New Zealand; Symptom Flare Up; U	2021
Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial. Medicine, 2022, May-06, Volume: 101, Issue:18 Topics: Arthritis, Gouty; Colchicine; Delayed-Action Preparations; Double-Blind Method; Drugs, Chinese Herba	2022
Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout. The Journal of rheumatology, 2022, Volume: 49, Issue:12 Topics: Allopurinol; Follow-Up Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome	2022
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:2 Topics: Adult; Anaphylaxis; Arthritis, Gouty; Double-Blind Method; Gout; Gout Suppressants; Humans; Methotre	2023
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. European journal of medical research, 2023, Jan-06, Volume: 28, Issue:1 Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Probenecid; Symptom	2023
Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:7 Topics: Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; T	2023
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial. Trials, 2023, Apr-19, Volume: 24, Issue:1 Topics: Gout; Gout Suppressants; Humans; Kidney; Multicenter Studies as Topic; Pragmatic Clinical Trials as	2023
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Annals of the rheumatic diseases, 2023, Volume: 82, Issue:12 Topics: Adult; Allopurinol; Colchicine; Gout; Gout Suppressants; Humans; Symptom Flare Up; Treatment Outcome	2023
Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. Frontiers in endocrinology, 2023, Volume: 14 Topics: Acupuncture Therapy; Gout; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Single-Blin	2023
UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. Joint bone spine, 2020, Volume: 87, Issue:6 Topics: Aged; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Male; Middle Aged; Prospective Stu	2020
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. Rheumatology (Oxford, England), 2021, 09-01, Volume: 60, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Febuxostat; Female; Gout; Gout Suppressa	2021
Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial. Clinical rheumatology, 2022, Volume: 41, Issue:1 Topics: Allopurinol; Double-Blind Method; Gout; Gout Suppressants; Humans; Symptom Flare Up; Time-to-Treatme	2022
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Annals of the rheumatic diseases, 2018, Volume: 77, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Dose-Response Relationship, Drug; Febuxo	2018
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the rheumatic diseases, 2017, Volume: 76, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Double	2017

Article	Year
Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study. International journal of rheumatic diseases, 2022, Volume: 25, Issue:2 Topics: Aged; Female; Gout; Gout Suppressants; Humans; Length of Stay; Male; Middle Aged; Native Hawaiian or	2022
Gout Storm. The American journal of case reports, 2021, Sep-20, Volume: 22 Topics: Colchicine; Gout; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Symptom Flare Up; Uric Acid	2021
IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype. Rheumatology (Oxford, England), 2022, 08-30, Volume: 61, Issue:9 Topics: Animals; Arthritis, Gouty; Glycogen Synthase Kinase 3 beta; Gout; Humans; Inflammation; Interleukin-	2022
One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis research & therapy, 2022, 04-20, Volume: 24, Issue:1 Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Uric Acid	2022
[Gout]. Zeitschrift fur Rheumatologie, 2022, Volume: 81, Issue:5 Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid	2022
Upregulated expression of FFAR2 and SOC3 genes is associated with gout. Rheumatology (Oxford, England), 2023, 02-01, Volume: 62, Issue:2 Topics: Cytokines; Gout; Humans; Hyperuricemia; Symptom Flare Up; Uric Acid	2023
A rare presentation of a first gout flare. Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3 Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid	2023
Ultrasonography in the prediction of gout flares: a 12-month prospective observational study. Rheumatology (Oxford, England), 2023, 03-01, Volume: 62, Issue:3 Topics: Gout; Humans; Inflammation; Prospective Studies; Symptom Flare Up; Ultrasonography; Uric Acid	2023
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an Arthritis research & therapy, 2022, 08-25, Volume: 24, Issue:1 Topics: Gout; Gout Suppressants; Humans; Male; Methotrexate; Polyethylene Glycols; Symptom Flare Up; Treatme	2022
Gout Flares and Intercritical Gout: Do they Play a Significant Role in Predicting Cardiovascular Events? Current vascular pharmacology, 2022, Volume: 20, Issue:6 Topics: Cardiovascular Diseases; Chronic Disease; Gout; Humans; Symptom Flare Up; Uric Acid	2022
Predictors of Patient and Physician Assessments of Gout Control. Arthritis care & research, 2023, Volume: 75, Issue:6 Topics: Allopurinol; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. The Journal of rheumatology, 2023, Volume: 50, Issue:4 Topics: Adult; COVID-19; COVID-19 Testing; Gout; Gout Suppressants; Humans; Polymerase Chain Reaction; Preva	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. Rheumatology (Oxford, England), 2023, 07-05, Volume: 62, Issue:7 Topics: Gout; Gout Suppressants; Humans; Male; Prospective Studies; Symptom Flare Up; Uric Acid	2023
Plasma adsorption in refractory chronic gouty arthritis flare: A case report. Frontiers in immunology, 2022, Volume: 13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl	2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report. Frontiers in immunology, 2022, Volume: 13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl	2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report. Frontiers in immunology, 2022, Volume: 13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl	2022
Plasma adsorption in refractory chronic gouty arthritis flare: A case report. Frontiers in immunology, 2022, Volume: 13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl	2022
Gout Flare and Cardiovascular Events-Reply. JAMA, 2023, 01-03, Volume: 329, Issue:1 Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid	2023
Gout Flare and Cardiovascular Events. JAMA, 2023, 01-03, Volume: 329, Issue:1 Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid	2023
Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology (Oxford, England), 2023, 12-01, Volume: 62, Issue:12 Topics: Absenteeism; Efficiency; Female; Gout; Humans; Male; Middle Aged; Quality of Life; Surveys and Quest	2023
Unusual Cause of Cord Compression in a Patient with Chronic Lymphocytic Leukemia. The American journal of case reports, 2023, Mar-23, Volume: 24 Topics: Aged; Gout; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Spinal Cord Compression; Symptom F	2023
The risk of venous thromboembolism increases within one month of gout flare: comment on the article by Cipolletta et al. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:10 Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Venous Thromboembolism	2023
Monosodium urate crystals alter the circadian clock in macrophages leading to loss of NLRP3 inflammasome repression: Implications for timing of the gout flare. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023, Volume: 37, Issue:6 Topics: ARNTL Transcription Factors; Caspases; Circadian Clocks; Gout; Humans; Inflammasomes; Interleukin-1b	2023
Beliefs about medicines in gout patients: results from the NOR-Gout 2-year study. Scandinavian journal of rheumatology, 2023, Volume: 52, Issue:6 Topics: Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Longitudinal Studies; Medica	2023
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study. Annals of internal medicine, 2023, Volume: 176, Issue:8 Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Gout; Hospit	2023
Cohort study investigating gout flares and management in UK general practice. BMC primary care, 2023, Nov-22, Volume: 24, Issue:1 Topics: Cohort Studies; General Practice; Gout; Gout Suppressants; Humans; Male; Symptom Flare Up; United Ki	2023
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study. RMD open, 2023, 12-01, Volume: 9, Issue:4 Topics: Cholesterol, LDL; Female; Gout; Humans; Life Style; Male; Middle Aged; Symptom Flare Up; Uric Acid	2023
Risk of gout flares after vaccination. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:8 Topics: Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid; Vaccination	2021
Postoperative Recurrent Gout Flares: A Cross-sectional Study From China. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:5 Topics: China; Cross-Sectional Studies; Gout; Gout Suppressants; Humans; Symptom Flare Up; Uric Acid	2020
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. Joint bone spine, 2020, Volume: 87, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Necrosis; N	2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology (Oxford, England), 2020, 09-01, Volume: 59, Issue:9 Topics: Adult; Age of Onset; ATP Binding Cassette Transporter, Subfamily G, Member 2; Europe; Female; Geneti	2020
Study on the relationship between FFA and gout flare. Clinical rheumatology, 2020, Volume: 39, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Biomarkers; Cholesterol, LDL; Fatty Acids, Noneste	2020
Risk factors of ultrasound-detected tophi in patients with gout. Clinical rheumatology, 2020, Volume: 39, Issue:6 Topics: Adult; Aged; Ankle Joint; Female; Glomerular Filtration Rate; Gout; Humans; Knee Joint; Logistic Mod	2020
The effect of reducing systemic inflammation on serum urate. Rheumatology (Oxford, England), 2020, Oct-01, Volume: 59, Issue:10 Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Blood Sedimentation; C-Rea	2020
Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:11 Topics: Aged; Allopurinol; Disease Progression; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged;	2020
Inpatient gout flare is multifactorial: comment on "clinical characteristics and risk factors for gout flare during the postsurgical period". Advances in rheumatology (London, England), 2020, 08-26, Volume: 60, Issue:1 Topics: Gout; Humans; Inpatients; Risk Factors; Symptom Flare Up; Uric Acid	2020
[Gout]. Der Internist, 2021, Volume: 62, Issue:5 Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Symptom Flare Up; Uric Acid	2021
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD open, 2021, Volume: 7, Issue:1 Topics: Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Symptom Flare Up; Treatment Outcome; Uri	2021
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:11 Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Cohort Studies; Female; Gout; Gout Suppressants; Hum	2021
Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology (Oxford, England), 2022, 04-18, Volume: 61, Issue:SI Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Longitudinal Studies; Symptom Flare Up; Tomograph	2022
The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation. Rheumatology (Oxford, England), 2022, 04-11, Volume: 61, Issue:4 Topics: Gout; Gout Suppressants; Humans; Inpatients; Prospective Studies; Symptom Flare Up; Uric Acid	2022
Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. Obesity surgery, 2021, Volume: 31, Issue:10 Topics: Bariatric Surgery; Gout; Humans; Hyperuricemia; Obesity, Morbid; Symptom Flare Up; Uric Acid	2021
Management of Gout and Hyperuricemia in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:3 Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat;	2017
Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. The Journal of rheumatology, 2018, Volume: 45, Issue:3 Topics: Biomarkers; Clinical Trials as Topic; Gout; Humans; Observational Studies as Topic; Outcome Assessme	2018
Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study : MSU burden and risk of gout flare. Arthritis research & therapy, 2018, 09-17, Volume: 20, Issue:1 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Cost of Illness; Female; Follow-Up Studies; Gout; H	2018
Comparative Study of Real-Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics. Arthritis care & research, 2020, Volume: 72, Issue:8 Topics: Aged; Allopurinol; Clinical Decision Rules; Clinical Protocols; Female; Follow-Up Studies; Gout; Gou	2020
Clinical characteristics and risk factors for gout flare during the postsurgical period. Advances in rheumatology (London, England), 2019, 07-25, Volume: 59, Issue:1 Topics: Allopurinol; Blood Loss, Surgical; Female; Foot Joints; Gout; Gout Suppressants; Humans; Knee Joint;	2019
Seasonality of gout in Korea: a multicenter study. Journal of Korean medical science, 2015, Volume: 30, Issue:3 Topics: Alcohol Drinking; Arthritis, Gouty; Blood Pressure; Body Mass Index; Comorbidity; Female; Gout Suppr	2015

uric acid and Acute Symptom Flare